Episode 268: ESMO 2023: Enzalutamide and 177Lu-PSMA-617 in CRPC with Louise Emmett

We’re joined by Louise Emmett, MBChB, FRACP, MD, to discuss data presented at ESMO 2023 on the randomized phase 2 ENZA-p trial that analyzed the efficacy of enzalutamide and 177Lu-PSMA-617 for poor-risk, metastatic, castration-resistant prostate cancer.

Professor Emmett is a nuclear medicine physician and specializes in PET imaging for prostate cancer at St Vincent’s Hospital Sydney.